CIBERESUCICOVID is a fundamental study to improve care of critical patients of COVID-19. Its results will definitely contribute to improve diagnosis and treatment, to decrease mortality, and improve the quality of life of survivors

Collaborate with us!
Those interested in participating in the investigation may directly contact the Study Coordinator, Adrián Ceccato, by clicking on the “join the study” button.

Dr. Antoni Torres, a pneumologist at Hospital Clínic, head of the group applied Research in Respiratory Infections and Critically Ill Patients, and group leader of the CIBER of Respiratory Diseases (CIBERES), explains about the study of risk factors and prognosis of patients admitted to ICUs.

Description of the Study:

  • Title: Personalized Risk and Prognosis Factors and Follow-up at One Year of the Patients Hospitalized in the Spanish Intensive Care Units Infected with COVID-19 (CIBERESUCICOVID).
  • Principal Investigator: Antoni Torres Martí.
  • Co-Investigators: Ferran Barbé Illa, Ricard Ferrer, Jesús Bermejo, Alejandro Rodríguez, Rosario Menéndez and et al.
  • Centers of Implementation: At more than 50 Spanish ICUs.
  • Study Population: 5000 patients.

Objectives of the Study:

Principal Objective: To determine, through artificial intelligence analysis, which are the risk and prognosis factors of patients infected with COVID-19 that are hospitalized in the Spanish ICUs since the pandemic started in Spain and until it is finished.

Secondary Objectives:
(1) To perform the follow-up of patients since their release from the ICU and from the hospital until one year later, to determine mortality at six months and at one year, and the repercussions in respiratory and cardiovascular function, as well as in the quality of life.
(2) To perform the epigenetic study of those cases in which a blood sample is obtained.
(3) To evaluate the impact over the prognosis of a panel of biomarkers in physiological routes which are key in the pathogenesis of the disease, with the goal of identifying the treatments which are more likely to be successful in each patient.

More about this Study:

Added Value: CIBERESUCICOVID is a study that brings together the main Spanish scientific societies related to respiratory diseases with critical COVID-19 patients.

Logo Ciberes 1
Instituto de Salud Carlos III finances this study to improve care of critical COVID-19 patients.

Other Studies about Pharmacology:

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

ANTICOV Study: COVID-19 in Africa

Collaborate with ANTICOV study to treat COVID-19 in Africa.

Antibiotic prescription during the COVID-19 pandemic

Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.

Influenza Vaccination, ACEI and ARB in the Evolution of COVID-19

A study to determine if influenza vaccination or ACEI or ARB medication has effects on COVID-19.

Progesterone for the Treatment of COVID-19

Can sex hormones help men survive COVID-19? This study assesses the safety and efficacy of progesterone for the treatment of COVID-19 in hospitalized men.

PanCOVID19: Evaluating Pharmacological Treatments

Open, randomized, adaptive, phase III clinical trial study to evaluate the efficacy of various pharmacological alternatives in the treatment of severe infection in COVID-19 pediatric…

MMR Vaccine and the Immune Response to SARS-CoV-2

Is the MMR vaccine involved in the immune response to SARS-CoV-2? This study aims to answer that question by investigating the effect of the MMR…

AstraZeneca Study of COVID-19 Vaccine Candidate AZD1222

Clinical trial designed to determine if the vaccine candidate, AZD1222, can prevent symptomatic COVID-19.

Amantadine and COVID-19

Participate in this study and help us discover the role of Amantadine as a therapeutic alternative to fight COVID-19.

COVACTA Trial: TCZ as COVID-19 Treatment

COVACTA study aims to evaluate the efficacy and safety of tocilizumab (TCZ) in hospitalized patients with severe COVID-19 pneumonia.